Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.Drugs in R&D · 2017
   Pooled it
2. Pharmacogenomic diversity among Arab populations: A systematic review.iScience · 2026
   Article
3. Genetic variants ofJournal of Taibah University Medical Sciences · 2026
   Article
4. The Genetic Polymorphisms of CYP2C9 and VKORC1 in the Saudi Population and Their Impact on Anticoagulant Management.Medicina (Kaunas, Lithuania) · 2025
   Article
5. The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.BMC cardiovascular disorders · 2025
   Article
6. Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach.Heliyon · 2024
   Article
7. Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.Current vascular pharmacology · 2024
   Article
8. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.The pharmacogenomics journal · 2021
   Article
9. A review of clinical pharmacogenetics Studies in African populations.Personalized medicine · 2020
   Review
10. Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?European journal of clinical pharmacology · 2018
    Observational
11. Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.PloS one · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as